Name	Seok Jin KIM
Current Position & Affiliation	Professor Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine
Country	Korea
Major Field	Lymphoma

Educational Background

1988. 3 – 1994. 2 Bachelor's degree, College of Medicine, Korea University, Seoul, Korea

1995. 9 – 1997. 8 Master's degree, Graduate School of Korea University, Seoul, Korea

1997. 9 – 2003. 2 Ph.D., Graduate School of Korea University, Seoul, Korea

Professional Experience

1994. 3 – 1995. 2 Intern, Korea University Guro Hospital, Seoul, Korea

1995. 3 – 1999. 2 Residency of Internal medicine, Korea University Anam Hospital, Seoul, Korea

1999. 4 – 2002. 3 Officer in Army of Obligation

2002. 4 – 2003. 4 Fellowship of Hematology/Oncology, Korea University Medical Center, Seoul, Korea

2003. 5 – 2004. 8 Postdoctoral fellow, Medicine-Oncology, Duke University Medical Center, NC, USA

2004. 9 – 2008. 1 Assistant professor, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

2008. 2 – 2014. 3 Associate professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2014. 4 - Professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Other Experience and Professional Memberships

Korean Association of Internal Medicine, Korean Cancer Association
Korean Society of Hematology
Korean Society of Blood and Marrow Transplantation
American Society of Hematology

Main Scientific Publications

- Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma. **Kim SJ**, Lim JQ, Yoon SE, Yang DH, Lee JH, Oh SY, Choi YS, Jeong SH, Kim MK, Lim SN, Cho J, Park B, Ryu KJ, Choi S, Park Y,

Lim KMH, Binte Muhammad Taib NA, Ong CK, Lim ST, Kim WS. Blood. 2025 Mar 12:blood.2024027109.

- CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Kim J, Cho J, Lee MH, Yoon SE, Kim WS, **Kim SJ**. Blood. 2024 Aug 8;144(6):629-638.
- The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma. Yoon SE, Kang W, Choi S, Park Y, Chalita M, Kim H, Lee JH, Hyun DW, Ryu KJ, Sung H, Lee JY, Bae JW, Kim WS, **Kim SJ**. Blood. 2023 May 4;141(18):2224-2238.
- Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. Yoon SE, Jo H, Kang ES, Cho D, Cho J, Kim WS, **Kim SJ**. Bone Marrow Transplant. 2022 Apr;57(4):641-648
- Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Kang D, Yoon SE, Shin D, Lee J, Hong YS, Lee SK, Lee JE, Park YH, Ahn JS, Guallar E, Kim WS, Lee J, **Kim SJ**, Cho J. Blood Cancer J. 2021 Dec 14;11(12):200.
- Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. **Kim SJ**, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, Ryu KJ, Ko YH, Koh Y, Cho D, Lim ST, Beck Enemark M, D'amore F, Bjerre M, Ong CK, Kim WS. Blood. 2020 Dec 10;136(24):2754-2763
- Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. **Kim SJ**, Yoon SE, Kim WS. J Hematol Oncol. 2018 Dec 20;11(1):140.
- Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Jeong SH, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, Lee HW, Eom HS, Won JH, Kim WS, **Kim SJ**. Biol Blood Marrow Transplant. 2018 Dec;24(12):2471-2478.
- Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Kwong YL, **Kim SJ**, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d'Amore F, Schmitz N, Jaccard A, Kim WS. Ann Oncol. 2018 Jan 1;29(1):256-263.
- A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. **Kim SJ**, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. Lancet Oncol. 2016 Mar;17(3):389-400.
- A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. **Kim SJ**, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS. Ann Oncol. 2016 Apr;27(4):712-8.
- Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. **Kim SJ**, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Ann Oncol. 2016 Mar;27(3):508-13.

- Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. **Kim SJ**, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS; Asia Lymphoma Study Group. Lancet Haematol. 2015 Feb;2(2):e66-74.
- Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group. **Kim SJ**, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS; Asia Lymphoma Study Group. J Hematol Oncol. 2013 Nov 16;6:86.
- Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. **Kim SJ**, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS. Blood. 2011 Feb 10;117(6):1958-65.
- Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: Results from a prospective multicenter phase II study. **Kim SJ**, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Haematologica. 2010 Nov;95(11):1935-42.
- When do we need central nervous system prophylaxis in the patients with extranodal NK/T cell lymphoma, nasal type? **Kim SJ**, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS. Ann Oncol. 2010 May;21(5):1058-63.
- Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed stage IE/IIE nasal extranodal NK/T cell lymphoma: CISL study. **Kim SJ**, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS. Journal of Clinical Oncology 2009 Dec 10;27(35):6027-6032